ResultsIQ

ResultsIQ › Latest results › Gufic Biosciences Limited

Gufic Biosciences Limited Q1 FY27 earnings call summary

NSE: GUFICBIO · BSE: 509079

Earnings call of 17 Aug 2026, summarised by AI from the filing.

Gufic Biosciences Q1 FY27 revenue ₹260.8 cr, EBITDA ₹47.2 cr; guides 15-20% growth and Indore utilization at 40-45% by year-end.

Key takeaways

  1. Change Indore capacity utilization rose to close to 30-35% from 20-25% last year.
  2. Driver GLP-1 CMO operations started; traction expected from Q2, actual in Q3.
  3. Risk Indore EU certification awaited; margin expansion depends on it.

Original filing on BSE

Gufic Biosciences Limited Q1 FY27 results

As filed: Revenue ₹261 cr (+16% year on year), EBITDA ₹46.6 cr (+41% year on year), PAT ₹22.3 cr (+72% year on year), EBITDA margin 17.9% (+314 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹252 cr (+23% year on year), EBITDA ₹47.2 cr (+75% year on year), PAT ₹21.9 cr (+174% year on year), EBITDA margin 18.8% (+558 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 558 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +8.3% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹231 cr (+11% year on year), EBITDA ₹33.0 cr (−3% year on year), PAT ₹12.4 cr (−35% year on year), EBITDA margin 14.3% (−209 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 209 bps year on year. Profit fell 27% from last quarter. Share price after the results: −7.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹237 cr (+16% year on year), EBITDA ₹39.0 cr (+3% year on year), PAT ₹17.0 cr (−23% year on year), EBITDA margin 16.5% (−217 bps). Score 60 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin fell 217 bps year on year. Share price after the results: +9.4% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹224 cr (+10% year on year), EBITDA ₹33.0 cr (−8% year on year), PAT ₹13.0 cr (−38% year on year), EBITDA margin 14.7% (−300 bps). Score 26 of 100, Below trend. EBITDA margin fell 300 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +3.5% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹205 cr (+5% year on year), EBITDA ₹27.0 cr (−21% year on year), PAT ₹8.0 cr (−60% year on year), EBITDA margin 13.2% (−427 bps). Score 17 of 100, Below trend. EBITDA margin fell 427 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 58% from last quarter. Share price after the results: −10.7% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹208 cr (+3% year on year), EBITDA ₹34.0 cr (−8% year on year), PAT ₹19.0 cr (−14% year on year), EBITDA margin 16.4% (−197 bps). Score 25 of 100, Below trend. EBITDA margin fell 197 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 14% from last quarter.
  • Q2 FY25: Revenue ₹204 cr (−5% year on year), EBITDA ₹38.0 cr (−3% year on year), PAT ₹22.0 cr (−4% year on year), EBITDA margin 18.6% (+49 bps). Score 29 of 100, Below trend. EBITDA margin rose 49 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Gufic Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.